1 Title

- 2 Comparative evaluation of plasma biomarkers of Schistosoma haematobium infection in
- 3 endemic populations from Burkina Faso

4 Short title

5 Plasma biomarkers of Schistosoma haematobium infection

6 Authors

- 7 Mireille Ouedraogo 1-2-3, Jana Christina Hey 4, Stan Hilt 5, Veronica Rodriguez Fernandez
- 8 1, Doris Winter 4, Ravo Razafindrakoto 6, Pytsje Hoekstra 5, Youssouf Kabore 3, Marco
- 9 Fornili 7, Laura Baglietto 7, Issa Nebie 3, Govert J van Dam 5, Paul L Corstjens 8, Daniela
- 10 Fusco 4-9, David Modiano 2, Fabrizio Bruschi 1, Valentina D Mangano 1

11 Affiliations

12	1.	Dept. of Translational Research in Medicine and Surgery, University of Pisa, Italy

- 13 2. Dept. of Public Health and Infectious Diseases, University of Rome La Sapienza, Italy
- 14 3. Centre National de Recherche et Formation sur le Paludisme, Ouagadougou,
- 15 Burkina Faso
- 4. Dept. Infectious Diseases Epidemiology, Bernard Nocht Institute for Tropical
 Medicine, Germany
- 18 5. Dept. of Parasitology, Leiden University Medical Center, the Netherlands
- 19 6. Centre d'infectiologie Charles Merieux, Antananarivo, Madagascar
- 20 7. Dept. of Clinical and Experimental Medicine, University of Pisa, Italy NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 8. Dept. of Cell & Chemical Biology, Leiden University Medical Center, the Netherlands
- German Center for Infection Research, Hamburg Lübeck Borstel Riems,

23 Germany

24 @ valentina.mangano@unipi.it

25 Abstract

Infection with *Schistosoma haematobium* causes urogenital disease associated with organ disfunction, bleeding, pain, and higher susceptibility to infections and cancer. Timely and accurate diagnosis is crucial for prompt and appropriate treatment as well as surveillance efforts, and the use of plasma biomarkers offers important advantages over parasitological examination of urine, including increased sensitivity and the possibility to use the same specimen for multiple investigations.

The present study aims to evaluate the diagnostic performance of different plasma biomarkers in endemic populations from Burkina Faso, West Africa. *Schistosoma* spp. Circulating Anodic Antigen (CAA), cell free *S. haematobium* DNA (cfDNA), class M and G antibodies against *S. haematobium* Soluble Worm Antigen Preparation (SWAP) and Soluble Egg Antigen (SEA) were measured in 406 plasma samples. Results of each biomarker test were compared to those of CAA, a Composite Reference Standard (CRS) and Latent Class Analysis (LCA).

An identical proportion of positive samples (29%) was observed as a result of CAA and cfDNA testing, with a substantial agreement (84%, Cohen k=0.62) between the results of the two tests, and a comparable agreement with the results of CRS and LCA. A higher positivity was observed, as expected, as a result of specific antibody testing (47%-72%), with IgG showing
a higher agreement than IgM with the three references. Also, higher IgG levels were
observed in current vs past infection, and ROC analysis identified optimal cutoff values for
improved testing accuracy.

This study provides compelling evidence that can inform the choice of the most appropriate diagnostic plasma biomarker for urogenital schistosomiasis in endemic areas, depending on the purpose, context, and available resources for testing. Either CAA or cfDNA testing can be used for the diagnosis of patients and for epidemiological investigations, even in absence of urine filtration microscopy, whereas anti-SWAP or anti-SEA IgG can be employed for surveillance and integrated monitoring of control interventions against poverty-associated diseases.

53

54 Keywords

55 Schistosomiasis, Schistosoma haematobium, diagnosis, plasma biomarkers, Neglected

- 56 Tropical Diseases, Burkina Faso
- 57

58 Author summary

59 Urogenital schistosomiasis is a chronic debilitating disease affecting populations living in 60 Africa and the Middle East and showing a strong association with poverty. Accurate 61 detection of infection is important both for disease treatment and surveillance. Several tests

based on detection in plasma of parasite protein (CAA), parasite DNA or parasite-specific 62 host antibodies (IgM and IgG against SWAP and SEA antigens) are available and this study 63 aims at comparing them to evaluate their accuracy. The comparison showed that tests based 64 on parasite CAA or DNA yield very similar results and therefore the test of choice for 65 diagnosis or epidemiological investigations can be based on laboratory resources. 66 Additionally, the comparison showed that IgG against SWAP and SEA outperform IgM, and 67 that high accuracy can be achieved by identifying an optimal level to determine positivity 68 (cut-off), making these antibody tests ideal for surveillance purposes. 69

71 MAIN TEXT

72 Introduction

Human schistosomiasis is a poverty-associated parasitic diseases caused by trematode blood flukes of the genus *Schistosoma*. It is estimated that 250 million people are infected in 78 endemic countries, and that 90% of cases occur in Sub-Saharan Africa (SSA) [1-3].

S. haematobium, endemic in Africa and the Middle East, and since recent years in some areas 76 of Europe [4-6], is the only species causing urogenital disease. Infection occurs by contact 77 with fresh-water bodies infested with free-swimming cercariae larvae released by specific 78 intermediate snail hosts of the genus Bulinus. Cercariae penetrate the skin of the human 79 host, shed their fork and become schistosomula, which then migrate via venous circulation 80 to the lungs, the heart and the liver where they mature to the adult stage. Adult worms exit 81 the liver via the portal vein system and reach the venules of the bladder, where they 82 reproduce and gravid females lay eggs. While most eggs remain trapped in venules and 83 body tissues, some are eliminated with urine. When the human host discharges urine in 84 fresh-water bodies, the eggs hatch and release miracidia, which penetrate the snail host and 85 transform into sporocysts. After two generation of sporocysts larval reproduction, these 86 87 transform into cercariae, able to initiate a new transmission cycle [7-9].

The disease is mostly accounted by immunopathogenic responses to the worms' eggs accumulated around bladder and ureters resulting in granuloma formation and tissue fibrosis. Clinical manifestations include haematuria, obstructive uropathy, kidney damage and squamous cell carcinoma [7-9]. In females, genital schistosomiasis (FGS) causes

ulcerative lesions and fibrosis in vagina, cervix and uterus, resulting in bleeding, pain and
higher risk of HIV infection [10-11]. Control of schistosomiasis mainly focuses on reducing
disease burden through periodic, large-scale population treatment with praziquantel, but
more comprehensive approaches include water, hygiene and sanitation strategies, health
education and snail control [2-3].

Diagnosis of schistosomiasis is fundamental for appropriate treatment of symptomatic 97 individuals as well as for monitoring the success of control efforts, and a variety of direct 98 99 (detecting the parasite or parasite molecules) and indirect (detecting the human immune responses to the parasite) laboratory methods are available, each with different advantages 100 101 and disadvantages. Microscopic examination of urine samples (urine filtration microscopy) for detection of S. haematobium eggs has optimal specificity based on distinct 102 morphological features. However, sensitivity is hampered by the irregular timing of eggs 103 release in urine and by their limited number, particularly in low intensity infections, and the 104 105 examination of at least three specimens is required [12-13]. Other direct methods include the detection of intestinal antigens regurgitated by Schistosoma adult worms and therefore 106 107 released in circulation, namely Circulating Cathodic Antigen (CCA) and Circulating Anodic Antigen (CAA), in either urine or serum/plasma samples by immunological assays such as 108 ELISA and ICT, including the point-of-care CCA (POC-CCA) test and the upconverting particle 109 lateral flow CAA (UCP-LF CAA) test [14]. Compared to CCA, CAA testing has shown a better 110 sensitivity for the diagnosis of infection by different Schistosoma species, including S. 111 haematobium, and in areas of low endemicity [15]. It has also been reported that CAA 112 concentration shows little day to day fluctuations, positively correlates with the number of 113

adult worms, and decreases sharply after drug treatment, establishing it as a valuable test 114 for both diagnosis and follow-up [16]. Nonetheless, it must be noted that infection with 115 larval stages cannot be diagnosed by such antigen tests. Detection of cell-free DNA (cfDNA) 116 of schistosomes in either stool/urine or plasma by molecular assays represents a promising 117 method for early direct diagnosis, since it can detect all stages of infection including larval 118 stages, and since optimal analytical sensitivity and specificity can be achieved by choice of 119 multi-copy specific targets [17]. For S. haematobium, Real Time PCR protocols based on the 120 detection of Dra1, a repeat sequence specific of this species and representing >15% of its 121 genome, have been recently developed and tested in migrant and travellers as well as 122 residents in endemic areas [18-22]. However, cfDNA may circulate for some time after 123 124 successful treatment and its detection might not therefore always indicate current infection [17]. Regarding indirect methods, these are based on the detection of specific antibodies 125 against parasite antigens in serum/plasma samples by immunological methods such as 126 127 ELISA, ICT and more recently Luminex [23-24]. The main advantage of these methods is increased sensitivity compared to urine filtration microscopy, as demonstrated in non-128 129 endemic contexts [25-26]. However, as production of antibodies by plasma cells only starts about 1 week after exposure to a given antigen, a temporal delay is to be expected between 130 infection and the detection of specific antibodies. More importantly, antibodies can still be 131 detectable in plasma after drug treatment and parasite death, both because of antigen 132 persistence and continued exposure to the immune system, and because of the long half-133 life of class G immunoglobulins (Ig). Therefore, seropositivity might reflect either history of 134 infection or current infection or both. Antigens employed for S. haematobium serology have 135

long included soluble excretory/secretory products from the different stages, such as Cercarial Antigen Preparation (CAP), Soluble Worm Adult Preparation (SEA) and Soluble Egg Antigen (SEA) [21, 27], and, more recently, recombinant proteins of the tetraspanin family that were identified as promising candidates through immunomic analyses [28-29]. It is noteworthy that no commercial in vitro diagnostic tests for the specific diagnosis of *S*. *haematobium* exist to date.

As described above, several assays are available for laboratory diagnosis of S. haematobium 142 using plasma samples. The use of plasma samples offers the important advantage of 143 allowing the simultaneous detection of biomarkers of infection with different pathogens in 144 145 the same specimen. This approach enables increased efficiency not only in the diagnosis of concomitant infections or the differential diagnosis of infections with overlapping clinical 146 features in patients, but also in conducting epidemiological studies and surveillance activities 147 of different infectious diseases such as malaria and NTDs, including the integrated 148 149 monitoring of control interventions impact [30-32]. A further advantage is the possibility of retrospective analysis of archived plasma samples for further investigations. 150

Despite the benefits offered by plasma assays for *S. haematobium* diagnosis, to the best of our knowledge, a comparative evaluation of their diagnostic performance has not yet been conducted in endemic populations. To this aim, we took advantage of archived plasma samples collected during malariological surveys in an area of *S. haematobium* and malaria co-endemicity in Burkina Faso [33].

157 Methods

158 Study design

The present study aimed at measuring plasma biomarkers of *S. haematobium* infection in samples collected during a cross-sectional survey conducted among endemic populations from Burkina Faso, and at performing a comparative evaluation of their diagnostic performance.

The cross-sectional survey was conducted in August 2007 in two rural villages (Barkoumbilen and Barkoundouba) of shrubby savannah areas of Burkina Faso northeast of the capital town Ouagadougou, for malaria epidemiology purposes [34]. A 2 mL venous blood sample was collected from each participant in ethylenediaminetetraacetic acid (EDTA) tubes). Plasma was separated by centrifugation (3min at 2000 rpm), aliquoted and stored at -80°C until assays were performed. The study area is endemic for *S. haematobium* [1, 33]. Assays have been performed on 406 archived plasma samples to measure the following

170 biomarkers: Schistosoma spp. Circulating Anodic Antigen (CAA), S. haematobium cell-free circulating DNA (cfDNA), S. mansoni cfDNA, IgM and IgG against S. haematobium Soluble 171 Worm Adult Protein (SWAP) and Soluble Egg Antigen (SEA). The species-specific results of 172 cfDNA testing were used to confirm that the study area is endemic for S. haematobium only. 173 The evaluation of the diagnostic performance of the different biomarker tests was 174 conducted comparing the results to those of three different references (i.e. defining true 175 infection status): i) Circulating Anodic Antigen; ii) Composite Reference Standard; iii) Latent 176 Class Analysis. 177

178

179 Ethics statement

Study subjects or their guardians gave written informed consent for participation. The original malaria epidemiological study received approval from the ethical committee of the Ministry of Health of Burkina Faso (2007-048). The use of archived plasma samples for schistosomiasis research received further approval from the ethical committee of the Ministry of Health and Public Hygiene of Burkina Faso (2022-05-15).

185

186 Circulating Anodic Antigen

The Up-Converting Particle Lateral Flow (UCP-LF) assay was conducted in Leiden University 187 Medical Center, the Netherlands, to detect Circulating Anodic Antigen (CAA) in plasma 188 189 samples as previously described (SCAA20) [16, 35]. High Salt Lateral Flow (HSLF) buffer (100 mM HEPES pH 7·5, 270 mM NaCl, 0·5% v/v Tween-20, 1% w/v BSA, 50 μL) was pipetted into 190 the wells of a 96-wells microplate. Each plasma sample (50 µL) was mixed with an equal 191 192 volume of 4% trichloroacetic acid (TCA) and centrifuged for 5 minutes at 18,000 RCF to separate the supernatant from the pellet. The supernatant (20 μ L) and a UCP solution (50 μ L) 193 containing reporter particles (400 nm Y₂O₂S:Yb³⁺,Er³) conjugated with mouse monoclonal 194 anti-CAA antibody (25 µg/mg) were pipetted in the microplate wells. After an incubation of 195 1 hour at 37°C with shaking (900 rpm), LF strips with a test line comprising 200 ng mouse 196 monoclonal anti-CAA antibody were added into the wells. A dilution series of a sample with 197 198 known CAA concentration (pg/ml) was included in the microplate and used as a standard curve to quantify CAA concentrations and to validate the threshold of the assay (10 pg/ml). 199 Strips were incubated overnight and scanned with an UPCON reader (980 nm excitation, 540 200

nm emission; Labrox Oy, Turku, Finland) for analysis. A threshold of 10 pg/ml (SCAA20, wet test format) was used to define CAA positivity [16, 35]. CAA levels were defined based on concentration ranges as follows: level 0=0-9 pg/ml range; level 1=10-99 pg/ml range; level 2=100-999 pg/ml range; level 3=1000-9999 pg/ml range; level 4=10000-100000 pg/ml range.

206

207 Cell-free circulating DNA

208 Cell free circulating DNA (cfDNA) was extracted from 100 µL plasma samples using the QIA amp Min Elute cfDNA Mini Kit according to the manufacturer's protocol. Real Time PCR was 209 210 performed at the Bernard Nocht Institute for Tropical Medicine, Germany, to amplify and detect S. heamatobium (Dra1) and S. mansoni (Sm1-7) target sequences (Sh-Forward Primer: 211 5'-GATCTCACCTATCAGACG AAAC-3', Sh-Reverse Primer: 5'-TCACAACGATACGACCAAC-3', 212 5'-Joe-TGTTGGAAGZGCCTGTTTCGCAA-BHQ1-3'; Sh-Probe: Sm-Forward Primer: 5'-213 214 CAACCGTTCTATGAA AATCGTTGT-3', Sm-Reverse Primer : 5'-CCA CGCTCTCGCAAATAATCT-3', Sm-Probe: 5'-Fam-TCCGAAACCACTGGACGGATTTTTATGAT-BHQ1-3') 215 previously as 216 described [21-22]. Primers and probe were included for the detection of Phocid herpesvirus (PhHV) DNA as internal PCR control (PhHV—Forward Primer: 5' GGG CGA ATC ACA GAT TGA 217 ATC 3', PhHV—Reverse Primer: 5' GCG GTT CCA AAC GTA CCA A 3', PhHV—Probe: 5' Cy5.5-218 TTT TTA TGT GTC CGC CAC CA-BBQ 3'). Briefly, the reaction was performed in a total volume 219 220 reaction of 25 µL containing 12.5 µl HotStarTag Mastermix (Qiagen, Hilden, Germany), 5 mM MgCl2, 500 nM of each Schistosoma primer, 250 nM of each Schistosoma probe, 40 nM of 221 the PhHV primer, 50 nM of the PhHV probe, 1.425 µg of the PhHV DNA template, 0.04 µg/µl 222

bovine serum albumin and 5 μL of DNA eluate. The amplification reaction (15 minutes at
95°C followed by 50 cycles of 15 seconds at 95°C and 60 seconds at 60°C with an initial
touchdown from 65°C to 60°C in the first 11 cycles) was conducted using the Corbett RotorGene 6000 (Qiagen) and results were analysed with the RotorGene 6000 Software v.7.87
(Qiagen). Samples with a clean sigmoid curve within the PCR cycles were considered positive.

228

229 Specific immunoglobulins

Specific IgM and IgG against S. haematobium Soluble Worm Adult Protein (SWAP) and 230 Soluble Egg Antigen (SEA) were measured by ELISA using an in house protocol adapted from 231 Mutapi and colleagues [27] as previously described [33]. Antigens were purchased from the 232 233 Theodor Bilharz Institute, Giza, Egypt. A volume of 100 µL antigen (5µg/mL for SWAP and 234 10µg/mL for SEA) in coating buffer (0.5 M sodium carbonate pH 9.6) was added per well in 96-wells plates (Nunc Immunosorp), and plates were incubated overnight at 4°C. After 3 235 236 washings (PBS-0.03 % Tween 20, PBS-T), 200µL blocking buffer (5 % skimmed milk powder in PBS/T) was added per well and plates incubated 2h at room temperature (RT). After 3 237 238 washings, plasma samples were added in duplicate in blocking buffer with a total volume of 100µL (1:200 dilution for IgM and 1:100 dilution for IgG) and plates were incubated 2h at RT. 239 240 After three washings 100 µL HRP-anti-human-IgG (Dako) at 1:1000 dilution in PBS-T was added and plates incubated for 2h at RT. After six washings 100 µL OPD (Sigma) substrate 241 solution was added, and plates incubated for 20 min in the dark at RT. A volume of 25 µL of 242 H₂SO₄ 1 M stop solution was added and plates were read with Synergy HT Biotek reader at 243 244 the absorbance of 492 nm. A standard curve consisting of a 5-point dilution series of a pool

of positive control (patients with positive result of urine filtration microscopy) samples was 245 included in each plate as well as a negative control consisting of a pool of negative control 246 (naïve blood donors) samples and a blank control containing no plasma. The OD value of 247 the blank control was subtracted from the OD values of test samples, and those were then 248 fitted to account for experimental variation using the standard curves (fitted OD, fOD). The 249 cut-off used for positivity was the mean absorbance plus 3 standard deviation of negative 250 control samples (cutoff = mean OD neg + 3SD neg). Logarithm transformation has been 251 applied to fOD values (logfOD) to normalise their distribution. 252

253

254 Statistical analysis

In reporting binary (i.e. positive/negative) test results, the proportion of positive results was
computed with its 95% Confidence Interval (CI), shown using barplots and compared
between population groups by logistic regression.

In reporting quantitative (i.e. antibody levels or antigen concentration) test results, the distribution was shown using boxplots and compared between population groups by linear regression. Correlation between quantitative test results was displayed using scatter plots and assessed by Spearman test.

The diagnostic performance of each test has been evaluated by comparison of binary results with three references: i) Circulating Anodic Antigen; ii) Composite Reference Standard; iii) Latent Class Analysis. For each comparison, sensitivity and specificity with their respective 95% CI were computed, as well as overall agreement and Cohen's k statistics. Cohen's k was interpreted as follows: values \leq 0 as no agreement, 0.01–0.20 as none to slight, 0.21–0.40 as fair, 0.41– 0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1.00 as almost perfect agreement.

269 CAA was chosen as a reference since it is a validated marker of infection [15-16].

A Composite Reference Standard (CRS) was defined as follows: a sample was considered positive if one or both direct (i.e. CAA and/or cfDNA) test results were positive, while it was considered negative if both direct tests results were negative. The rationale of the algorithm is to define infection status based on direct markers tests, and it assumes that both CAA and cfDNA have 100% specificity [36].

Latent Class Analysis (LCA) modelling with two clusters was used to define a binary (positive/negative) LCA reference [26]. The model included all available manifest variables: CAA (positive/negative), cfDNA (positive/negative), anti-SWAP IgM level (log10-fOD), anti-SWAP IgG level (log10-fOD), anti-SEA IgG level (log10-fOD), anti-SEA IgM level (log10-fOD). The LCA reference therefore defines infection status based on the results of all direct and indirect biomarker tests.

Receiver Operating Characteristic (ROC) analysis was used to evaluate the ability of antibody 281 levels (logfOD) to discriminate between positive and negative reference results, by 282 calculating Area Under Curve values and by computing specificity, sensitivity and overall 283 agreement for each possible cut-off value. An optimal cut-off value was identified by filtering 284 values associated with >75% agreement, sensitivity and specificity, ordering them from 285 286 higher to lower agreement, sensitivity and specificity, and selecting the top value. A cutoff Antibody Index (AI) was calculated as the ratio between the value of the cutoff and the value 287 288 of the negative control.

All analyses were performed in STATA v13.00, except for the LCA analysis that was conducted using using R v. 4.3.1 and its package *flexmix*.

291

292 **Results**

Real Time PCR did detect S. haematobium cfDNA in the study sample, but not S. mansoni 293 cfDNA (data not shown), as expected from the literature [1]. Therefore, it can be assumed 294 that CAA in this area is a product of S. haematobium and therefore a biomarker of urogenital 295 schistosomiasis. The proportion of positive results for each plasma biomarker of S. 296 haematobium infection is shown in Table 1. CAA and cfDNA tests result in an identical 297 298 proportion of positive subjects, equal to 29%. Specific antibody tests result in a higher proportion of positive subjects, ranging from 47% to 72%, with anti-SEA Ig showing higher 299 300 positivity than anti-SWAP Ig.

301

Table 1. Proportion of positive subjects for plasma biomarkers of S. haematobium

304 infection.

The table shows, for each plasma biomarker of *S. haematobium* infection, the number of positive subjects (N+), the number of subjects in the study population (Ntot), and the proportion of positive subjects (%) with its lower (LCL) and upper (UCL) 95% Confidence Limits.

Marker	Positive subjects									
Marker	N+	Proportion+ (%)	LCL	UCL						
CAA	118	406	29.1	24.8	33.7					
cfDNA	118	406	29.1	24.8	33.7					
anti-SWAP IgM	192	406	47.3	42.5	52.2					
anti-SWAP IgG	223	406	54.9	50.0	59.7					
anti-SEA IgM	292	406	71.9	67.3	76.1					
anti-SEA IgG	282	406	69.5	64.8	73.8					

309

310

The breadth of antibody response to S. haematobium (Sh) antigens (i.e. the total number of 311 specific lq for which a positive result was observed) and the different patterns of positivity 312 are shown in Table 2. Overall, 15% of subjects were seronegative for anti-Sh Ig. Among 313 subjects who were seropositive for only one specific Ig (12%), the majority was positive for 314 anti-SEA IgG. Among subjects who were seropositive for two specific Ig (18%), the two most 315 and equally frequent combinations were anti-SWAP IgM/anti-SWAP IgG and anti-SWAP 316 IgG/anti-SEA IgG. Among subjects who were seropositive for three specific Ig (26%), the 317 majority was positive for all Ig except anti-SWAP IgM. Finally, about 29% of subjects were 318 positive for all four specific Iq. In order to investigate the diagnostic potential of indirect 319

320	markers compared to direct ones, the positivity of CAA and cfDNA direct markers according
321	to the breadth of the anti-Sh Ig response was assessed by logistic regression analysis. It can
322	be observed that both CAA (OR=2.4, 95%CI=1.9-3.0, p-value<0.001) and cfDNA (OR=2.6,
323	95% CI=2.1-3.4, p-value<0.001) positivity increase significantly with the number of positive
324	specific Ig (Figure 1).

Table 2. Patterns of antibody response against S. *haematobium* **antigens.**

326 The table shows the breadth of the antibody response to *S. haematobium* antigens

327 (number of positive anti-Sh lg) and the different positivity patterns of lgM and lgG

responses to SWAP and SEA antigens, with their relative proportion (%) in the total studypopulation.

Bre	adth	Pattern					
anti-Shla+ (N)	Propertion (%)	anti-S	SWAP	anti-	SEA	Propertien (%)	
		lgM	lgG	IgM	lgG		
0	14.5					14.5	
						2.2	
1	12.3					0.3	
	12.0					4.7	
						5.2	
	17.5					5.9	
						1.2	
2						1.5	
L						3.7	
						5.2	
						1.5	
						1.0	
3	26.4					6.2	
						17.7	
4	29.3					29.3	
Total	100		Tc	otal		100	

The formal evaluation of the diagnostic performance of the different biomarkers was conducted by comparing each test results to those of three different references (i.e. "true" infection status): i) Circulating Anodic Antigen (CAA); ii) Composite Reference Standard (CRS); iii) Latent Class Analysis (LCA). For each comparison, sensitivity and specificity were calculated as well as the overall agreement.

337

In comparison with CAA as the reference test (Table 3), cfDNA showed 73% sensitivity and 338 339 89% specificity, with a Cohen's k of 0.64, indicating substantial agreement. Indeed, despite resulting in an identical proportion of positive samples, the two tests did not yield identical 340 results (Supplementary Figure 1). The comparison of CAA and cfDNA results stratified by 341 CAA level shows that the proportion of "false negative" cfDNA results decreases significantly 342 343 with increasing CAA levels (OR=0.23, 95% CI=0.17-0.31, p-value<0.001; Figure 2). Among specific antibodies, Cohen's k ranged from 0.09 to 0.37, indicating none to fair agreement, 344 345 with the best performance being observed for anti-SWAP IgG, showing 88% sensitivity and 59% specificity. 346

Table 3. Diagnostic performance of plasma biomarkers compared to Circulating

349 Anodic Antigen.

350 The table shows, for each plasma biomarker of *S. haematobium* infection, the sensitivity

(Se) and specificity (Sp) with their lower (LCL) and upper (UCL) 95% Confidence Limits, the

- 352 overall agreement and the Cohen's K value, when compared to Circulating Anodic Antigen
- 353 as the reference.

Markor	Circulating Anodic Antigen									
Marker	Se	LCL	UCL	Sp	LCL	UCL	Agreement	Cohen's K		
CAA	-	-	-	-	-	-	-	-		
cfDNA	73%	65%	81%	89%	85%	93%	84%	0.62		
anti-SWAP IgM	55%	46%	64%	56%	50%	62%	56%	0.09		
anti-SWAP IgG	88%	82%	94%	59%	53%	64%	67%	0.37		
anti-SEA IgM	94%	90%	98%	37%	32%	43%	54%	0.22		
anti-SEA IgG	95%	91%	99%	41%	35%	47%	57%	0.25		

354

355

A CRS was built using an algorithm that classified a sample as positive if it exhibits positive 356 results of either or both direct marker tests (CAA+ OR cfDNA+), and as negative if they 357 exhibit negative results of both direct marker tests (CAA- AND cfDNA-), irrespectively of the 358 results of indirect marker tests. This CRS resulted in a 37% proportion of positive subjects 359 (data not shown). In comparison with the CRS (Table 4), both CAA and cfDNA showed 79% 360 sensitivity and 100% specificity (as expected), with an overall almost perfect agreement (92%, 361 Cohen's K=0.82). Among specific antibodies, Cohen's k ranged from 0.11 to 0.43, indicating 362 slight to moderate agreement, and once again the best performance was observed for anti-363 SWAP IgG, showing 85% sensitivity and 63% specificity. 364

Table 4. Diagnostic performance of plasma biomarkers compared to a Composite

366 **Reference Standard.**

367 The table shows, for each plasma biomarker of *S. haematobium* infection, the sensitivity (Se)

and specificity (Sp) with their lower (LCL) and upper (UCL) 95% Confidence Limits, the overall

369 agreement and the Cohen's K value, when compared to a Composite Reference Standard.

Markar	Composite Reference Standard									
Marker	Se	LCL	UCL	Sp	LCL	UCL	Agreement	Cohen's K		
CAA	79%	72%	85%	100%	100%	100%	92%	0.82		
cfDNA	79%	72%	85%	100%	100%	100%	92%	0.82		
anti-SWAP IgM	55%	47%	63%	57%	51%	63%	56%	0.11		
anti-SWAP IgG	85%	79%	90%	63%	57%	68%	71%	0.43		
anti-SEA IgM	94%	90%	98%	41%	35%	47%	61%	0.29		
anti-SEA IgG	94%	90%	98%	45%	39%	51%	63%	0.33		

370

Finally, result of each biomarker were compared with results of LCA modelling (Table 5), where a sample was classified as positive or negative based on all available biomarker data, and that resulted in a 35% proportion of positive subjects (data not shown). In comparison with the LCA, both CAA and cfDNA showed substantial agreement, with Cohen's k equal to 0.62 and 0.75 respectively. Among specific antibodies, Cohen's k ranged from 0.15 to 0.55, indicating slight to moderate agreement. Consistently with previous comparisons, the best performance was observed for anti-SWAP IgG, showing 97% sensitivity and 67% specificity.

Table 5. Diagnostic performance of plasma biomarkers compared to Latent Class

379 Analysis classification.

380 The table shows, for each plasma biomarker of *S. haematobium* infection, the sensitivity (Se)

and specificity (Sp) with their lower (LCL) and upper (UCL) 95% Confidence Limits, the overall

agreement and the Cohen's K value, when compared to Latent Class Analysis classification.

Marker	Latent Class Analysis									
indi Kei	Se	LCL	UCL	Sp	LCL	UCL	Agreement	Cohen's K		
CAA	67%	60%	75%	92%	89%	95%	83%	0.62		
cfDNA	76%	69%	83%	97%	94%	99%	89%	0.75		
anti-SWAP IgM	58%	50%	66%	58%	52%	64%	58%	0.15		
anti-SWAP IgG	95%	92%	99%	67%	61%	73%	77%	0.55		
anti-SEA IgM	99%	97%	100%	43%	37%	49%	63%	0.34		
anti-SEA IgG	100%	100%	100%	47%	41%	53%	66%	0.39		

383

Receiver Operating Curve (ROC) analysis was conducted to further evaluate the diagnostic performance of *S. haematobium* specific antibodies. The Area Under Curve (AUC) statistics, a measure of the ability of a marker to correctly classify positive and negative cases as defined by a reference standard, was computed for each antibody test against the three references (CAA, CRS, LCA). The comparison of AUC allows to identify the marker showing the best diagnostic performance: the highest AUC value was observed for anti-SEA IgG, followed closely by anti-SWAP IgG, for each reference (Table 6; Supplementary Figures 2-4).

Table 6. Diagnostic performance of antibody tests resulting from ROC analysis.

The table shows, for each *S.haematobium* antibody test, the Area Under Curve (AUC) resulting from ROC analysis conducted to evaluate the diagnostic performance compared to Circulating Anodic Antigen (CAA), Composite Reference Standard (CRS), and Latent Class Analysis classifications.

Marker	Area Under Curve (AUC)						
Marker	CAA	CRS	LCA				
anti-SWAP IgM	0.567	0.597	0.635				
anti-SWAP IgG	0.826	0.832	0.915				
anti-SEA IgM	0.765	0.796	0.861				
anti-SEA IgG	0.878	0.901	0.995				

397

For anti-SWAP and anti-SEA IgG, ROC analysis was employed for further comparison with 398 CAA to generate Sensitivity/Specificity plots (Figure 3), which show that selecting a higher 399 cutoff value compared to the analytical one would result in better diagnostic performances. 400 For instance, for anti-SWAP IgG, a cut-off of 0.196 log(fOD) corresponding to a 2.3 Antibody 401 Index (AI) would result in 75% sensitivity, 76% specificity and 76% agreement. Similarly, for 402 403 anti-SEA IgG, a cut-off of 0.242 log(fOD) corresponding to a 4.5 AI would result in 82% sensitivity, 80% specificity and 81% agreement (data not shown). Also, the distribution of 404 antibody levels according to CAA positivity was investigated, as well as the correlation 405 between antibody levels and CAA concentration ranges. The distribution of antibody levels 406 was significantly higher in subjects that were positive to CAA than in negative subjects, for 407 both anti-SWAP IgG (Expβ=15.3, 95%CI=9.8-23.8, p-value<0.001; Figure 4, left panel) and 408 anti-SEA IgG (ExpB=13.3, 95%CI=9.4-18.8, p-value<0.001; Figure 4, right panel). Finally, a 409

scarce albeit significant positive correlation was observed between antibody levels and CAA
concentration, both for anti-SWAP IgG (Spearman P-value<0.001, rho=0.425; Figure 5 left
panel) and anti-SEA IgG (Spearman P-value<0.001, rho=0.437; Figure 5, right panel).

413

414 **Discussion**

In summary, the measurement of plasma biomarkers of S. haematobium infection among 415 406 subjects living in rural endemic villages of Burkina Faso, West Africa, has shown that 416 both CAA and cfDNA testing result in a 29% proportion of positive samples. A 29% 417 prevalence of urogenital schistosomiasis in this area confirms an estimate for Burkina Faso 418 based on systematic review of survey data and geostatistical modelling (26.3%) [1]. However, 419 it likely represents an underestimation, as suggested by the observation that CRS and LCA 420 show a proportion of positive subjects of 37% and 35%, respectively. Indeed, despite an 421 identical proportion of positive samples identified by CAA and cfDNA testing, the two tests 422 did not yield identical results. Discordant CAA negative/cfDNA positive results could be 423 attributed to differences in the stage specificity of the two markers, with cfDNA detecting all 424 stages including larval ones while CAA detecting adults [37], and/or by recently cleared 425 infections with cfDNA persisting in circulation longer than CAA [38]. On the other hand, 426 discordant CAA positive/cfDNA negative results could be attributed to a suboptimal cfDNA 427 sensitivity at low CAA concentrations because of an insufficient plasma volume used for 428 nucleic acid extraction in this study (1000µl of plasma was used in a previous work [22] 429 compared to the 100µl used in the present study), an hypothesis supported by the 430

observation that the proportion of "false negative" cfDNA results decreases significantly with increasing CAA levels. Despite some discordant results, there was a substantial agreement between CAA and cfDNA testing, along with a comparable agreement with the results of CRS and LCA. Taken together, the identical proportion of positive samples identified by the two tests, and the substantial agreement of the results, indicate that CAA and cfDNA are equivalent good plasma biomarkers of infection in areas of *S. haematobium* endemicity.

As expected, specific antibody testing resulted in a much higher proportion of positive 437 samples (47%-72% range), as the presence of specific antibodies might reflect not only 438 current infection but past exposure to the parasite. Interestingly, it was observed that the 439 breadth of the antibody response to S. haematobium was positively associated with both 440 CAA and cfDNA positivity, indicating that subjects harbouring antibodies against multiple S. 441 haematobium antigens are more likely to be currently infected. The analysis of individual 442 responses has shown that IgG against SWAP and SEA exhibit a higher agreement with the 443 444 three references (CAA, CRS and LCA) compared to IgM. When compared to CAA, ROC analysis confirmed a better ability of IgG to distinguish positive and negative subjects, and 445 446 showed that higher cutoff values result in greatly enhanced specificity and overall diagnostic performance of these indirect biomarkers. Indeed, IgG levels were significantly higher in CAA 447 positive than CAA negative subjects, indicating that antibody levels are increased in subjects 448 with current infection compared to subjects with past exposure, and highlighting the 449 450 relevance of the choice of appropriate cutoff values for accurate detection of infection. However, only a moderate correlation between IgG antibody levels and CAA concentration 451

452 was observed, indicating that IgG levels cannot be used as markers of *S. haematobium* 453 infection intensity.

One limitation of the present study is the lack of results from urine filtration microscopy, as urine specimens were not collected during the original investigation survey. Also, the antibody response to CAP was not investigated, as this antigen could not be procured at the time of analysis. Since CAP is a cercarial antigen, data would have been beneficial for interpreting discordant results between cfDNA and CAA testing, by either supporting or refusing the hypothesis that very recent infections with larval stages would be detected by cfDNA but not CAA.

Despite the above limitations, the comparative evaluation of plasma biomarkers presented 461 herein represents, to our knowledge, the first conducted among endemic populations. The 462 data provide valuable insights that can inform the choice of testing to be employed in areas 463 endemic for urogenital schistosomiasis, depending on the purpose, context, needs and 464 available laboratory resources. For diagnostic "test-to-treat" purposes, when infection with 465 S. haematobium is suspected, either CAA or cfDNA testing can be performed for 466 confirmation, even in the absence of urine filtration microscopy, while anti-SWAP and anti-467 SEA IgG testing could be performed for supporting evidence. A similar strategy is currently 468 recommended in non-endemic countries for the diagnosis of schistosomiasis [39]. It is 469 noteworthy that only cfDNA is a species-specific marker, and therefore CAA positive results 470 do not exclude an infection with other Schistosoma species. However, only CAA provides a 471 quantitative measurement (i.e. CAA concentration) associated with worm burden that can 472 be used for follow-up of treated patients [40]. Likewise, for epidemiological investigations, 473

either CAA or cfDNA testing can be performed to assess infection in areas of S. haematobium 474 endemicity depending on laboratory resources, since they are equivalent good markers. As 475 mentioned above, it should also be considered that only cfDNA testing would provide a 476 confirmation of the species while only CAA testing results can be analyzed as a quantitative 477 variable which might be an advantage for association studies. Finally, for surveillance 478 purposes, once the appropriate cut-off has been established for a given epidemiological 479 context to ensure optimal agreement with markers of current infection, anti-SWAP or anti-480 SEA IgG testing could be either employed, with the important advantages of allowing 481 multiplexing with other antibody tests as well as automation. 482

The availability of different accurate diagnostic tests for *S. haematobium* infection based on the detection of plasma biomarkers represents a significant development in the control of urogenital schistosomiasis in endemic areas.

486

487 Authors contributions

488 MO, JH, SH, VRF, DW, RR and PH conducted the experiments. YK and IN coordinated the 489 cross-sectional survey. MF and LB performed Latent Class Analysis. GJvD, PC, DF, DM, FB and 490 VM designed experiments and contributed experimental resources. FB, DM and VDM 491 designed the study. VDM performed data analyses and wrote the manuscript. All authors 492 revised and approved the final version of the manuscript.

493

495 Funding

496 No specific funding was obtained to conduct the research herein presented. M Ouedraogo 497 was supported by the PhD School in Microbiology, Infectious Diseases and Public Health, 498 Sapienza University of Rome. VD Mangano was supported by the University of Pisa and the 499 Minister of University and Research. D Fusco was supported by the German Centre for 500 Infection.

501

502 Acknowledgments

The authors would like to thank participants for making the study possible; physicians, nurses, laboratory technicians, data management staff at Centre National de Recherche et Formation sur le Paludisme for their skilled work; Zeno Bisoffi at Centre for Tropical Diseases in Negrar, Italy, for contributing sera samples of patients infected with *S. haematobium*; Carlota Dobano, Gemma Moncunill and colleagues at Barcelona Institute for Global Health, Spain, for critical discussion of the results; the Italian Network for Neglected Tropical Diseases for promoting research, control and advocacy activities for the fight against NTDs.

510

511 Data availability

512 Data have been deposited in the Repository Figshare and are (DOI: 513 10.6084/m9.figshare.25311364).

514

515 **REFERENCES**

1. Lai YS, Biedermann P, Ekpo UF, Garba A, Mathieu E, Midzi N, Mwinzi P, N'Goran EK,

- 518 Raso G, Assaré RK, Sacko M, Schur N, Talla I, Tchuenté LA, Touré S, Winkler MS,
- 519 Utzinger J, Vounatsou P. Spatial distribution of schistosomiasis and treatment needs
- in sub-Saharan Africa: a systematic review and geostatistical analysis. Lancet Infect
 Dis. 2015 Aug;15(8):927-40. doi: 10.1016/S1473-3099(15)00066-3.
- WHO. 2020 Ending the neglect to attain the sustainable development goals: a road
 map for neglected tropical diseases 2021–2030. Geneva, Switzerland: World Health
 Organization.
- 3. WHO. 2022 WHO guideline on control and elimination of human schistosomiasis.
 Geneva, Switzerland: World Health Organization.
- 4. Kincaid-Smith J, Tracey A, de Carvalho Augusto R, Bulla I, Holroyd N, Rognon A, Rey
 O, Chaparro C, Oleaga A, Mas-Coma S, Allienne JF, Grunau C, Berriman M, Boissier J,
 Toulza E. Morphological and genomic characterisation of the Schistosoma hybrid
 infecting humans in Europe reveals admixture between Schistosoma haematobium
 and Schistosoma bovis. PLoS Negl Trop Dis. 2021 Dec 23;15(12):e0010062. doi:
 10.1371/journal.pntd.0010062.
- Rothe C, Zimmer T, Schunk M, Wallrauch C, Helfrich K, Gültekin F, Bretzel G, Allienne
 JF, Boissier J. Developing Endemicity of Schistosomiasis, Corsica, France. Emerg
 Infect Dis. 2021 Jan;27(1):319-21. doi: 10.3201/eid2701.204391.
- 5366. Salas-Coronas J, Bargues MD, Lozano-Serrano AB, Artigas P, Martínez-Ortí A, Mas-537Coma S, Merino-Salas S, Abad Vivas-Pérez JI. Evidence of autochthonous
- 538 transmission of urinary schistosomiasis in Almeria (southeast Spain): An outbreak
- analysis. Travel Med Infect Dis. 2021 Nov-Dec;44:102165. doi:

540 10.1016/j.tmaid.2021.102165.

- 541 7. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014
 542 Jun 28;383(9936):2253-64. doi: 10.1016/S0140-6736(13)61949-2
- 543 8. Gabrielli AF & Garba Djirmay A, 2022. Schistosomiasis. In: Encyclopedia of Infection
 544 and Immunity, Volume 2, 2022, Pages 666–677, Elsevier 2022.

545	9. Othman A., El Ridi R. Schistosomiasis. In: F. Bruschi (ed.), Helminth Infections and
546	their Impact on Global Public Health, 2nd edition, Springer-Verlag Wien 2022.
547	10. Hotez PJ, Engels D, Gyapong M, Ducker C, Malecela MN. Female Genital
548	Schistosomiasis. N Engl J Med. 2019 Dec 26;381(26):2493-2495. doi:
549	10.1056/NEJMp1914709.
550	11. Hotez PJ, Harrison W, Fenwick A, Bustinduy AL, Ducker C, Sabina Mbabazi P, Engels
551	D, Floerecke Kjetland E. Female genital schistosomiasis and HIV/AIDS: Reversing the
552	neglect of girls and women. PLoS Negl Trop Dis. 2019 Apr 4;13(4):e0007025. doi:
553	10.1371/journal.pntd.0007025
554	12. WHO (1991) Basic laboratory methods in medical parasitology. In: Basic Malaria
555	Microscopy, Part I, World Heath Organization, Geneva.
556	13. Knopp S, Ame SM, Hattendorf J, Ali SM, Khamis IS, Bakar F, et al. Urogenital
557	schistosomiasis elimination in Zanzibar: accuracy of urine filtration and haematuria
558	reagent strips for diagnosing light intensity Schistosoma haematobium infections.
559	Parasit Vectors. 2018;11(1):552
560	14. Ochodo EA, Gopalakrishna G, Spek B, Reitsma JB, van Lieshout L, Polman K,
561	Lamberton P, Bossuyt PM, Leeflang MM. Circulating antigen tests and urine reagent
562	strips for diagnosis of active schistosomiasis in endemic areas. Cochrane Database
563	Syst Rev. 2015 Mar 11;2015(3):CD009579. doi: 10.1002/14651858.CD009579.pub2.
564	15. Knopp S, Corstjens PL, Koukounari A, Cercamondi CI, Ame SM, Ali SM, de Dood CJ,
565	Mohammed KA, Utzinger J, Rollinson D, van Dam GJ. PLoS Negl Trop Dis. Sensitivity
566	and Specificity of a Urine Circulating Anodic Antigen Test for the Diagnosis of
567	Schistosoma haematobium in Low Endemic Settings. 2015 May 14;9(5):e0003752.
568	doi: 10.1371/journal.pntd.0003752.
569	16. Corstjens PLAM, de Dood CJ, Knopp S, Clements MN, Ortu G, Umulisa I, Ruberanziza
570	E, Wittmann U, Kariuki T, LoVerde P, Secor WE, Atkins L, Kinung'hi S, Binder S,
571	Campbell CH, Colley DG, van Dam GJ. Circulating Anodic Antigen (CAA): A Highly
572	Sensitive Diagnostic Biomarker to Detect Active Schistosoma Infections-

Improvement and Use during SCORE. Am J Trop Med Hyg. 2020 Jul;103(1_Suppl):5057. doi: 10.4269/ajtmh.19-0819.

- 575 17. Ullah H, Arbab S, Li K, Khan MIU, Qadeer A, Muhammad N. Schistosomiasis related
 576 circulating cell-free DNA: A useful biomarker in diagnostics. Mol Biochem Parasitol.
 577 2022 Sep;251:111495. doi: 10.1016/j.molbiopara.2022.111495.
- 18. Cnops L, Soentjens P, Clerinx J, Van Esbroeck M. A Schistosoma haematobiumspecific real-time PCR for diagnosis of urogenital schistosomiasis in serum samples
 of international travelers and migrants. PLoS Negl Trop Dis. 2013 Aug 29;7(8):e2413.
 doi: 10.1371/journal.pntd.0002413.
- 19. Guegan H, Fillaux J, Charpentier E, Robert-Gangneux F, Chauvin P, Guemas E,
 Boissier J, Valentin A, Cassaing S, Gangneux JP, Berry A, Iriart X. Real-time PCR for
 diagnosis of imported schistosomiasis.PLoS Negl Trop Dis. 2019 Sep
 11;13(9):e0007711. doi: 10.1371/journal.pntd.0007711.
- 20. Keller D, Rothen J, Dangy JP, Saner C, Daubenberger C, Allan F, Ame SM, Ali SM,
 Kabole F, Hattendorf J, Rollinson D, Seyfarth R, Knopp S. Performance of a real-time
 PCR approach for diagnosing Schistosoma haematobium infections of different
 intensity in urine samples from Zanzibar. Infect Dis Poverty. 2020 Sep 4;9(1):128. doi:
 10.1186/s40249-020-00726-y.
- 21. Frickmann H, Lunardon LM, Hahn A, Loderstädt U, Lindner AK, Becker SL,
 Mockenhaupt FP, Weber C, Tannich E. Evaluation of a duplex real-time PCR in
 human serum for simultaneous detection and differentiation of Schistosoma
 mansoni and Schistosoma haematobium infections cross-sectional study. Travel
 Med Infect Dis. 2021 May-Jun;41:102035. doi: 10.1016/j.tmaid.2021.102035.
- 596 22. Gruninger SK, Rasamoelina T, Rakotoarivelo RA, Razafindrakoto AR, Rasolojaona ZT,
 597 Rakotozafy RM, Soloniaina PR, Rakotozandrindrainy N, Rausche P, Doumbia CO,
 598 Jaeger A, Zerbo A, von Thien H, Klein P, van Dam G, Tannich E, Schwarz NG, Lorenz
 599 E, May J, Rakotozandrindrainy R, Fusco D. Prevalence and risk distribution of
 600 schistosomiasis among adults in Madagascar: a cross-sectional study. Infect Dis
 601 Poverty. 2023 Apr 25;12(1):44. doi: 10.1186/s40249-023-01094-z.

- 23. Hinz R, Schwarz NG, Hahn A, Frickmann H. Serological approaches for the diagnosis
 of schistosomiasis A review. Mol Cell Probes. 2017 Feb;31:2-21. doi:
- 604 10.1016/j.mcp.2016.12.003. Epub 2016 Dec 13.
- 24. Santano R, Rubio R, Grau-Pujol B, Escola V, Muchisse O, Cuamba I, Vidal M, Ruiz-
- Olalla G, Aguilar R, Gandasegui J, Demontis M, Jamine JC, Cossa A, Sacoor C, Cano J,
- 607 Izquierdo L, Chitnis CE, Coppel RL, Chauhan V, Cavanagh D, Dutta S, Angov E, van
- Lieshout L, Zhan B, Muñoz J, Dobaño C, Moncunill G. Evaluation of antibody
- serology to determine current helminth and Plasmodium falciparum infections in a
- co-endemic area in Southern Mozambique. PLoS Negl Trop Dis. 2022 Jun
- 611 21;16(6):e0010138. doi: 10.1371/journal.pntd.0010138.
- 612 25. Kinkel HF, Dittrich S, Bäumer B, Weitzel T. Evaluation of eight serological tests for
 613 diagnosis of imported schistosomiasis. Clin Vaccine Immunol. 2012 Jun;19(6):948-53.
 614 doi: 10.1128/CVI.05680-11
- 26. Beltrame A, Guerriero M, Angheben A, Gobbi F, Requena-Mendez A, Zammarchi L,
 Formenti F, Perandin F, Buonfrate D, Bisoffi Z. PLoS Accuracy of parasitological and
 immunological tests for the screening of human schistosomiasis in immigrants and
 refugees from African countries: An approach with Latent Class Analysis. Negl Trop
 Dis. 2017 Jun 5;11(6):e0005593. doi: 10.1371/journal.pntd.0005593
- 27. Mutapi F, Ndhlovu PD, Hagan P, Woolhouse ME. A comparison of humoral
 responses to Schistosoma haematobium in areas with low and high levels of
 infection. Parasite Immunol. 1997 Jun;19(6):255-63. doi: 10.1046/j.13653024.1997.d01-206.x.
- 28. Pearson MS, Tedla BA, Mekonnen GG, Proietti C, Becker L, Nakajima R, Jasinskas A,
 Doolan DL, Amoah AS, Knopp S, Rollinson D, Ali SM, Kabole F, Hokke CH, Adegnika
 AA, Field MA, van Dam G, Corstjens PLAM, Mduluza T, Mutapi F, Oeuvray C, Greco
 B, Chaiyadet S, Laha T, Cai P, McManus DP, Bottazzi ME, Felgner PL, Sotillo J, Loukas
 A. Immunomics-guided discovery of serum and urine antibodies for diagnosing
 urogenital schistosomiasis: a biomarker identification study. Lancet Microbe. 2021
- 630 Nov;2(11):e617-e626. doi: 10.1016/S2666-5247(21)00150-6.

- 29. Mekonnen GG, Tedla BA, Pearson MS, Becker L, Field M, Amoah AS, van Dam G,
 Corstjens PLAM, Mduluza T, Mutapi F, Loukas A, Sotillo J. Characterisation of
- 633 tetraspanins from Schistosoma haematobium and evaluation of their potential as
- novel diagnostic markers. PLoS Negl Trop Dis. 2022 Jan 24;16(1):e0010151. doi:
- 635 10.1371/journal.pntd.0010151.
- 30. Lammie PJ, Moss DM, Brook Goodhew E, Hamlin K, Krolewiecki A, West SK, Priest
 JW. Development of a new platform for neglected tropical disease surveillance. Int J
- 638 Parasitol. 2012 Aug;42(9):797-800. doi: 10.1016/j.ijpara.2012.07.002
- 31. Arnold BF, van der Laan MJ, Hubbard AE, Steel C, Kubofcik J, Hamlin KL, Moss DM,
 Nutman TB, Priest JW, Lammie PJ. Measuring changes in transmission of neglected
 tropical diseases, malaria, and enteric pathogens from quantitative antibody levels.
 PLoS Negl Trop Dis. 2017 May 19;11(5):e0005616. doi:
- 643 10.1371/journal.pntd.0005616.
- 32. Chan Y, Fornace K, Wu L, Arnold BF, Priest JW, Martin DL, Chang MA, Cook J,
 Stresman G, Drakeley C. Determining seropositivity-A review of approaches to
 define population seroprevalence when using multiplex bead assays to assess
 burden of tropical diseases. PLoS Negl Trop Dis. 2021 Jun 28;15(6):e0009457. doi:
 10.1371/journal.pntd.0009457.
- 33. Mangano VD, Bianchi C, Ouedraogo M, Kabore Y, Corran P, Silva N, Sirima SB, Nebie
 I, Bruschi F, Modiano D. Antibody response to Schistosoma haematobium and other
 helminth species in malaria-exposed populations from Burkina Faso. Acta Trop. 2020
 May;205:105381. doi: 10.1016/j.actatropica.2020.105381.
- 34. Mangano VD, Kabore Y, Bougouma EC, Verra F, Sepulveda N, Bisseye C,
- 654 Santolamazza F, Avellino P, Tiono AB, Diarra A, Nebie I, Rockett KA, Sirima SB,
- 655 Modiano D; MalariaGEN Consortium. Novel Insights Into the Protective Role of
- 656 Hemoglobin S and C Against Plasmodium falciparum Parasitemia. J Infect Dis. 2015
- 657 Aug 15;212(4):626-34. doi: 10.1093/infdis/jiv098.
- 35. Corstjens PL, De Dood CJ, Kornelis D, Fat EM, Wilson RA, Kariuki TM, Nyakundi RK,
 Loverde PT, Abrams WR, Tanke HJ, Van Lieshout L, Deelder AM, Van Dam GJ. Tools

660	for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-
661	flow based assays and upconverting phosphor labels. Parasitology. 2014
662	Dec;141(14):1841-55. doi: 10.1017/S0031182014000626.
663	36. Hoekstra PT, Madinga J, Lutumba P, van Grootveld R, Brienen EAT, Corstjens PLAM,
664	van Dam GJ, Polman K, van Lieshout L. Diagnosis of Schistosomiasis without a
665	Microscope: Evaluating Circulating Antigen (CCA, CAA) and DNA Detection Methods
666	on Banked Samples of a Community-Based Survey from DR Congo. Trop Med Infect
667	Dis. 2022 Oct 19;7(10):315. doi: 10.3390/tropicalmed7100315.
668	37. Weerakoon KG, Gordon CA, McManus DP. DNA Diagnostics for Schistosomiasis
669	Control. Trop Med Infect Dis. 2018 Aug 1;3(3):81. doi: 10.3390/tropicalmed303008
670	38. Guegan H, Fillaux J, Charpentier E, Robert-Gangneux F, Chauvin P, Guemas E,
671	Boissier J, Valentin A, Cassaing S, Gangneux JP, Berry A, Iriart X. Real-time PCR for
672	diagnosis of imported schistosomiasis. PLoS Negl Trop Dis. 2019 Sep
673	11;13(9):e0007711. doi: 10.1371/journal.pntd.0007711.
674	39. Comelli A, Genovese C, Gobbi F, Brindicci G, Capone S, Corpolongo A, Crosato V,
675	Mangano VD, Marrone R, Merelli M, Prato M, Santoro CR, Scarso S, Vanino E,
676	Marchese V, Antinori S, Mastroianni C, Raglio A, Bruschi F, Minervini A, Donà D,
677	Garazzino S, Galli L, Lo Vecchio A, Galli A, Dragoni G, Cricelli C, Colacurci N, Ferrazzi
678	E, Pieralli A, Montresor A, Richter J, Calleri G, Bartoloni A, Zammarchi L.
679	Schistosomiasis in non-endemic areas: Italian consensus recommendations for
680	screening, diagnosis and management by the Italian Society of Tropical Medicine
681	and Global Health (SIMET), endorsed by the Committee for the Study of
682	Parasitology of the Italian Association of Clinical Microbiologists (CoSP-AMCLI), the
683	Italian Society of Parasitology (SoIPa), the Italian Society of Gastroenterology and
684	Digestive Endoscopy (SIGE), the Italian Society of Gynaecology and Obstetrics
685	(SIGO), the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV),
686	the Italian Society of General Medicine and Primary Care (SIMG), the Italian Society
687	of Infectious and Tropical Diseases (SIMIT), the Italian Society of Pediatrics (SIP), the

688	Italian Society of Paediatric Infectious Diseases (SITIP), the Italian Society of Urology
689	(SIU). Infection. 2023 Oct;51(5):1249-1271. doi: 10.1007/s15010-023-02050-7.
690	40. Tamarozzi F, Ursini T, Hoekstra PT, Silva R, Costa C, Gobbi F, Monteiro GB, Motta L,
691	van Dam GJ, Corstjens PL, van Lieshout L, Buonfrate D. Evaluation of microscopy,
692	serology, circulating anodic antigen (CAA), and eosinophil counts for the follow-up
693	of migrants with chronic schistosomiasis: a prospective cohort study. Parasit Vectors.
694	2021 Mar 9;14(1):149. doi: 10.1186/s13071-021-04655-z.
695	

697 **FIGURES**

Figure 1. CAA and cfDNA positivity according to the breadth of the antibody





700

The figure shows the proportion of subjects showing results to CAA (blue) and cfDNA (green)

- testing according to the breadth of the antibody response to *S. haematobium* antigens. Bars
- represent proportion and whiskers represent the standard error of the proportion.

704

706 **Figure 2. Proportion of cfDNA negative results according to CAA levels.**

707



708

The figure shows the proportion of negative results according to CAA levels, i.e. concentration ranges. Bars represent proportion and whiskers represent the standard error of the proportion.

712

714 Figure 3. Cutoff levels of anti-SWAP and anti-SEA IgG and diagnostic performance



715 compared to Circulating Anodic Antigen.

- The figure shows the plot of sensitivity (blue) and specificity (red) compared to Circulating
- Anodic Antigen for each cutoff value of anti-SWAP IgG (left panel) and anti-SEA IgG (right
- panel). The grey vertical line indicates the analytical cutoff.

721 Figure 4. Distribution of anti-SWAP and anti-SEA IgG levels according to Circulating

722 Anodic Antigen positivity.

723





The figure shows the boxplot distribution of anti-SWAP (left panel) and anti-SEA (right panel) IgG levels according to Circulating Anodic Antigen (CAA) positivity (negative subjects, Neg; positive subjects; Pos). The horizontal line represents the 50% percentile (median), the box lower and upper limits represent the 25% and 75% percentiles respectively, and lower and upper whiskers represent the 5% and 95% percentiles respectively, while the dots are outliers of the distribution.

731

733 Figure 5. Correlation of anti-SWAP and anti-SEA IgG levels with Circulating Anodic



734 Antigen concentration.

The figure shows scatterplots illustrating the correlation of anti-SWAP IgG levels (log fOD; left panel) and anti-SEA IgG levels (log fOD; right panel) with CAA concentration (log pm/ml). Dots represent actual data points, the line represent the fitted data, and the grey area represent the 95% confidence interval of the fitted line.

740

741

743 Figure 6. Sensitivity and specificity of *S. haematobium* plasma biomarkers compared

744 to Circulating Anodic Antigen, Composite Reference Standard and Latent Class

745 Analysis.



746

The figure shows forest plots of sensitivity (blue) and specificity (red) of different S.

haematobium plasma biomarkers compared to Circulating Anodic Antigen (CAA, left

panel), Composite Reference Standard (CRS, mid panel) and Latent Class Analysis (LCA,

right panel). Dots represent the estimate and whiskers represent the 95%Cl of the estimate.